Humana (NYSE:HUM) Releases FY24 Earnings Guidance

Humana (NYSE:HUM - Get Free Report) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of approx. $16.00 for the period, compared to the consensus estimate of $16.35.

Humana Stock Performance

HUM traded down $11.94 during trading on Wednesday, hitting $316.04. The stock had a trading volume of 3,488,066 shares, compared to its average volume of 2,006,808. The firm has a market capitalization of $38.13 billion, a P/E ratio of 15.95, a PEG ratio of 1.91 and a beta of 0.45. The company's 50-day moving average price is $329.86 and its 200 day moving average price is $398.38. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.59 and a current ratio of 1.59. Humana has a twelve month low of $299.23 and a twelve month high of $541.21.

Humana (NYSE:HUM - Get Free Report) last issued its earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.12 by $1.11. Humana had a return on equity of 19.44% and a net margin of 2.34%. The business had revenue of $29.61 billion during the quarter, compared to the consensus estimate of $28.52 billion. During the same period in the prior year, the business posted $9.38 EPS. The company's revenue for the quarter was up 10.7% on a year-over-year basis. On average, equities research analysts forecast that Humana will post 16.06 EPS for the current fiscal year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be given a $0.885 dividend. The ex-dividend date is Friday, June 28th. This represents a $3.54 annualized dividend and a dividend yield of 1.12%. Humana's dividend payout ratio is presently 17.86%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on HUM shares. Cantor Fitzgerald reissued a neutral rating and issued a $391.00 target price on shares of Humana in a research report on Wednesday, April 10th. StockNews.com lowered Humana from a strong-buy rating to a hold rating in a research note on Friday, January 26th. Argus cut Humana from a buy rating to a hold rating in a report on Wednesday, March 13th. TD Cowen decreased their price objective on shares of Humana from $427.00 to $396.00 and set a buy rating for the company in a research note on Tuesday, April 2nd. Finally, Stephens reduced their target price on shares of Humana from $550.00 to $430.00 and set an overweight rating on the stock in a report on Friday, January 26th. Eleven equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of Hold and an average target price of $454.63.

Insider Activity

In other news, Director Jorge S. Mesquita purchased 545 shares of the company's stock in a transaction on Tuesday, February 20th. The shares were bought at an average price of $367.09 per share, for a total transaction of $200,064.05. Following the completion of the purchase, the director now owns 2,578 shares of the company's stock, valued at $946,358.02. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.29% of the company's stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.